Evaxion Biotech, Pantherna Reveals Encouraging Data From mRNA-Based Cancer Vaccine – Evaxion Biotech (NASDAQ:EVAX)

Date:

  • Evaxion Biotech A/S EVAX and Pantherna Therapeutics GmbH announced a preclinical proof of concept for combining the two companies key technologies.
  • The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model when delivered using Pantherna’s proprietary lipid nanoparticle mRNA platform.
  • In continuation of these positive findings, Evaxion and Pantherna will further explore optimal LNP formulations to effectively deliver mRNA and DNA-encoded antigens identified by Evaxion’s AI platforms.
  • In November, Evaxion Biotech announced interim safety and immunogenicity data from the Phase 1/2a study of its DNA-based cancer immunotherapy, EVX-02.
  • EVX-02 is given with a checkpoint inhibitor and targets cancer mutations and neoantigens in patients with resected melanoma. 
  • In December, Evaxion signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB for the joint development of a novel cytomegalovirus (CMV) vaccine candidate.
  • Evaxion will use its proprietary AI platform, RAVEN, to design a next-generation vaccine candidate that elicits cellular and humoral/antibody responses. 
  • EVAX stock was up by 12% at one point in the trading session.
  • Price Action: EVAX shares are up 1.69% at $1.81 on the last check Wednesday.

Share post:

Subscribe

Popular

More like this
Related